ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
REVOLUTION Medicines Announces First Patient Dosed with RMC-4630
October 12, 2018REVOLUTION Medicines announced dosing of the first patient in a Phase 1, open-label, monotherapy dose-escalation and expansion study of RMC-4630, the company’s lead investigational drug candidate targeting the enzyme SHP2. -
Sanofi and REVOLUTION Medicines launch global partnership to develop potential first-in-class targeted treatments for multiple cancers
July 19, 2018Sanofi and REVOLUTION Medicines, Inc. today announced an exclusive worldwide partnership to develop and commercialize targeted therapies, based on the biology of the cellular enzyme SHP2, for patients with non-small lung cancer and other types of cancer c
Pharma Sources Insight January 2025
